To compare WHO first-line antiretroviral therapy ( ART ) with nonnucleoside reverse transcriptase inhibitors ( NNRTI ) - based regimen with a boosted protease inhibitor ( bPI ) regimen in a resource-limited setting regarding treatment outcome and emergence of drug resistance mutations ( DRMs ) .